Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom

Are adverse effects incorporated in economic models? An initial review of current practice

(2014) D Craig et al.   HEALTH TECHNOLOGY ASSESSMENT

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer

(2009) Heather Taffet Gold et al.   CANCER

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

(2009) Glenn E Palomaki et al.   GENETICS IN MEDICINE

Fish and chips all round? Regulation of DNA-based genetic diagnostics

(2009) Katherine Payne   HEALTH ECONOMICS

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan

(2009) Roberta Ferraldeschi et al.   PHARMACOGENOMICS

Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods

(2009) Laura Bojke et al.   VALUE IN HEALTH

Use of expert knowledge in evaluating costs and benefits of alternative service provisions: A case study

(2008) Paul H. Garthwaite et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Cost-effectiveness of123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

(2008) Angelo Antonini et al.   MOVEMENT DISORDERS

Cost–effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer

(2008) Marko Obradovic et al.   PHARMACOGENOMICS